CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore Amgen Research Munich's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 21, 2025
Patent NumberGrant DateTitleTotal Oppositions
Jul 10, 2024Dosing Regimen For Anti-Bcma Agents2
Mar 13, 2024Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains2
Mar 13, 2024Dosing Regimen For Anti-Bcma Agents3
Aug 23, 2023Risk-Stratification Of B-Precursor Acute Lymphoblastic Leukemia Patients1
Dec 22, 2021Bcma And Cd3 Bispecific T Cell Engaging Antibody Constructs1
Nov 25, 2020Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains2
Mar 18, 2020Methods For Treating Dlbcl1
Sep 11, 2019Binding Molecules For Bcma And Cd38
Aug 21, 2019Binding Molecules For Bcma And Cd37
Dec 26, 2018Risk-Stratification Of B-Precursor Acute Lymphoblastic Leukemia Patients1